{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:46:39Z","timestamp":1790793999263,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.yebeh.2021.108450","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T14:07:10Z","timestamp":1638454030000},"page":"108450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Prescription patterns and dosages of antiepileptic drugs in prevalent patients with epilepsy in Taiwan: A nationwide retrospective cross-sectional study"],"prefix":"10.1016","volume":"126","author":[{"given":"Chun-Yu","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Liang","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Po","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Nien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10172","key":"10.1016\/j.yebeh.2021.108450_b0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2021.108450_b0010","doi-asserted-by":"crossref","unstructured":"Song P, Liu Y, Yu X, Wu J, Poon AN, Demaio A, Wang W, Rudan I, Chan KY. Prevalence of epilepsy in China between 1990 and 2015: A systematic review and meta-analysis. J Glob Health 2017;7: 020706.","DOI":"10.7189\/jogh.07.020706"},{"issue":"586","key":"10.1016\/j.yebeh.2021.108450_b0015","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.3399\/bjgp11X572463","article-title":"Epilepsy mortality and risk factors for death in epilepsy: a population-based study","volume":"61","author":"Ridsdale","year":"2011","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.yebeh.2021.108450_b0020","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/epi.12557","article-title":"Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparison","volume":"55","author":"de Groot","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108450_b0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1528-1167.2009.02481.x","article-title":"Estimation of the burden of active and life-time epilepsy: a meta-analytic approach","volume":"51","author":"Ngugi","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108450_b0030","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.yebeh.2021.108450_b0035","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1212\/WNL.0000000000003685","article-title":"Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"88","author":"Harden","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108450_b0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/WNL.0000000000004094","article-title":"The incidence of SUDEP: a nationwide population-based cohort study","volume":"89","author":"Sveinsson","year":"2017","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108450_b0045","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1212\/WNL.0000000000008741","article-title":"Clinical risk factors in SUDEP: a nationwide population-based case-control study","volume":"94","author":"Sveinsson","year":"2020","journal-title":"Neurology"},{"issue":"9971","key":"10.1016\/j.yebeh.2021.108450_b0050","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","article-title":"Epilepsy: new advances","volume":"385","author":"Mosh\u00e9","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2021.108450_b0055","doi-asserted-by":"crossref","unstructured":"Neligan A, Bell GS, Shorvon SD, Sander JW. Temporal trends in the mortality of people with epilepsy: a review. Epilepsia 2010;51: 2241-6.","DOI":"10.1111\/j.1528-1167.2010.02711.x"},{"key":"10.1016\/j.yebeh.2021.108450_b0060","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/brain\/awh267","article-title":"Life expectancy in people with newly diagnosed epilepsy","volume":"127","author":"Gaitatzis","year":"2004","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.yebeh.2021.108450_b0065","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1111\/epi.13902","article-title":"Potential years lost and life expectancy in adults with newly diagnosed epilepsy","volume":"58","author":"Granbichler","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108450_b0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.yebeh.2021.108450_b0075","doi-asserted-by":"crossref","first-page":"e032551","DOI":"10.1136\/bmjopen-2019-032551","article-title":"Trends in antiepileptic drug treatment and effectiveness in clinical practice in England from 2003 to 2016: a retrospective cohort study using electronic medical records","volume":"9","author":"Powell","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.yebeh.2021.108450_b0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.yebeh.2018.05.019","article-title":"Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: a US database analysis","volume":"85","author":"Faught","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108450_b0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eplepsyres.2008.11.018","article-title":"Antiepileptic drug utilization in Taiwan: analysis of prescription using National Health Insurance database","volume":"84","author":"Hsieh","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108450_b0090","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology, ATC\/DDD index for antiepileptics, https:\/\/www.whocc.no\/atc_ddd_index\/?code=N03A; 2021 [accessed 20 March 2021]. In."},{"key":"10.1016\/j.yebeh.2021.108450_b0095","doi-asserted-by":"crossref","first-page":"117138","DOI":"10.1016\/j.jns.2020.117138","article-title":"Prevalence and predictors of post-stroke epilepsy among Ghanaian stroke survivors","volume":"418","author":"Sarfo","year":"2020","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108450_b0100","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/epi.13744","article-title":"The association between dementia and epilepsy: a systematic review and meta-analysis","volume":"58","author":"Subota","year":"2017","journal-title":"Epilepsia"},{"issue":"1-2","key":"10.1016\/j.yebeh.2021.108450_b0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eplepsyres.2013.02.002","article-title":"Prevalence of epilepsy in the People's Republic of China: a systematic review","volume":"105","author":"Gu","year":"2013","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108450_b0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1528-1157.1988.tb04405.x","article-title":"Prevalence of epilepsy in the Parsi community of Bombay","volume":"29","author":"Bharucha","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108450_b0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.expneurol.2014.04.009","article-title":"Sex differences in human epilepsy","volume":"259","author":"Savic","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.yebeh.2021.108450_b0120","doi-asserted-by":"crossref","unstructured":"Parko K, Thurman DJ. Prevalence of epilepsy and seizures in the Navajo Nation 1998-2002. Epilepsia 2009;50: 2180-5.","DOI":"10.1111\/j.1528-1167.2009.02140.x"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108450_b0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1528-1157.1996.tb00005.x","article-title":"Prevalence of epilepsy in the elderly: the Rotterdam Study","volume":"37","author":"Court","year":"1996","journal-title":"Epilepsia"},{"issue":"3-4","key":"10.1016\/j.yebeh.2021.108450_b0130","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000493484","article-title":"Aging and the epidemiology of epilepsy","volume":"51","author":"Beghi","year":"2018","journal-title":"Neuroepidemiology"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108450_b0135","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.seizure.2012.04.014","article-title":"Trends in antiepileptic drug utilisation in UK primary care 1993\u20132008: cohort study using the General Practice Research Database","volume":"21","author":"Nicholas","year":"2012","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/j.yebeh.2021.108450_b0140","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/ijms17081242","article-title":"The impact of anti-epileptic drugs on growth and bone metabolism","volume":"17","author":"Fan","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108450_b0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1517\/14740338.6.3.267","article-title":"Adverse effects of antiepileptic drugs on bone mineral density in children","volume":"6","author":"Gissel","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.yebeh.2021.108450_b0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.seizure.2020.10.018","article-title":"Current role of carbamazepine and oxcarbazepine in the management of epilepsy","volume":"83","author":"Beydoun","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108450_b0155","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1034\/j.1600-0404.2001.00197.x","article-title":"Antiepileptic drug utilization: a Danish prescription database analysis","volume":"104","author":"Rochat","year":"2001","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108450_b0160","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108450_b0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1535-7597.2005.05201.x","article-title":"Using current evidence in selecting antiepileptic drugs for use during pregnancy","volume":"5","author":"Pennell","year":"2005","journal-title":"Epilepsy Curr"},{"issue":"9","key":"10.1016\/j.yebeh.2021.108450_b0170","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1212\/WNL.0000000000008001","article-title":"Declining malformation rates with changed antiepileptic drug prescribing: an observational study","volume":"93","author":"Tomson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.108450_b0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.seizure.2019.04.003","article-title":"Risk of valproic acid-related alopecia: a systematic review and meta-analysis","volume":"69","author":"Wang","year":"2019","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108450_b0180","doi-asserted-by":"crossref","DOI":"10.1186\/s40780-017-0088-5","article-title":"Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases","volume":"3","author":"Hatahira","year":"2017","journal-title":"J Pharm Health Care Sci"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108450_b0185","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.108450_b0190","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.seizure.2020.01.009","article-title":"Long-term follow-up of post-stroke epilepsy after ischemic stroke: room for improved epilepsy treatment","volume":"76","author":"Redfors","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.108450_b0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.seizure.2018.08.001","article-title":"Randomized controlled trials of antiepileptic drugs for the treatment of post-stroke seizures: a systematic review with network meta-analysis","volume":"61","author":"Brigo","year":"2018","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108450_b0200","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000342669","article-title":"Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project)","volume":"34","author":"Consoli","year":"2012","journal-title":"Cerebrovasc Dis"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108450_b0205","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1755-5949.2011.00251.x","article-title":"Seizures and epilepsy in Alzheimer's disease","volume":"18","author":"Friedman","year":"2012","journal-title":"CNS Neurosci Ther"},{"issue":"10","key":"10.1016\/j.yebeh.2021.108450_b0210","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1468-1331.2007.01907.x","article-title":"Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study","volume":"14","author":"Belcastro","year":"2007","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108450_b0215","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000119103","article-title":"Epilepsy and dementia in the elderly","volume":"25","author":"Hommet","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108450_b0220","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00002512-200320020-00005","article-title":"Drug treatment of epilepsy in elderly people: focus on valproic Acid","volume":"20","author":"Stephen","year":"2003","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108450_b0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/10401230309085675","article-title":"The diverse roles of anticonvulsants in bipolar disorders","volume":"15","author":"Ketter","year":"2003","journal-title":"Ann Clin Psychiatry"},{"issue":"09","key":"10.1016\/j.yebeh.2021.108450_b0230","doi-asserted-by":"crossref","first-page":"438","DOI":"10.5414\/CPP44438","article-title":"Differences between prescribed daily doses and defined daily doses of antiepileptics\u2013therapeutic drug monitoring as a marker of the quality of the treatment","volume":"44","author":"Koristkova","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108450_b0235","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11096-017-0447-1","article-title":"Correlation between prescribed daily dose, seizure freedom and defined daily dose in antiepileptic drug treatment","volume":"39","author":"Horv\u00e1th","year":"2017","journal-title":"Int J Clin Pharm"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021007113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:45:05Z","timestamp":1761504305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021007113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":47,"alternative-id":["S1525505021007113"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108450","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescription patterns and dosages of antiepileptic drugs in prevalent patients with epilepsy in Taiwan: A nationwide retrospective cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108450"}}